vs
QuidelOrtho Corp（QDEL）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是QuidelOrtho Corp的1.3倍（$906.4M vs $699.9M），Rollins, Inc.净利率更高（11.9% vs -104.7%，领先116.6%），Rollins, Inc.同比增速更快（10.2% vs -3.7%），Rollins, Inc.自由现金流更多（$111.2M vs $-94.7M），过去两年Rollins, Inc.的营收复合增速更高（0.8% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
QDEL vs ROL — 直观对比
营收规模更大
ROL
是对方的1.3倍
$699.9M
营收增速更快
ROL
高出13.9%
-3.7%
净利率更高
ROL
高出116.6%
-104.7%
自由现金流更多
ROL
多$205.9M
$-94.7M
两年增速更快
ROL
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $906.4M |
| 净利润 | $-733.0M | $107.8M |
| 毛利率 | — | — |
| 营业利润率 | -100.7% | 16.1% |
| 净利率 | -104.7% | 11.9% |
| 营收同比 | -3.7% | 10.2% |
| 净利润同比 | -3583.4% | 2.5% |
| 每股收益（稀释后） | $-10.78 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | — | $912.9M | ||
| Q3 25 | $699.9M | $1.0B | ||
| Q2 25 | $613.9M | $999.5M | ||
| Q1 25 | $692.8M | $822.5M | ||
| Q4 24 | $707.8M | $832.2M | ||
| Q3 24 | $727.1M | $916.3M | ||
| Q2 24 | $637.0M | $891.9M |
净利润QDELROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | — | $116.4M | ||
| Q3 25 | $-733.0M | $163.5M | ||
| Q2 25 | $-255.4M | $141.5M | ||
| Q1 25 | $-12.7M | $105.2M | ||
| Q4 24 | $-178.4M | $105.7M | ||
| Q3 24 | $-19.9M | $136.9M | ||
| Q2 24 | $-147.7M | $129.4M |
营业利润率QDELROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | — | 17.5% | ||
| Q3 25 | -100.7% | 21.9% | ||
| Q2 25 | -29.4% | 19.8% | ||
| Q1 25 | 4.7% | 17.3% | ||
| Q4 24 | -14.2% | 18.1% | ||
| Q3 24 | 2.1% | 20.9% | ||
| Q2 24 | -18.4% | 20.4% |
净利率QDELROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | -104.7% | 15.9% | ||
| Q2 25 | -41.6% | 14.2% | ||
| Q1 25 | -1.8% | 12.8% | ||
| Q4 24 | -25.2% | 12.7% | ||
| Q3 24 | -2.7% | 14.9% | ||
| Q2 24 | -23.2% | 14.5% |
每股收益（稀释后）QDELROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | — | $0.24 | ||
| Q3 25 | $-10.78 | $0.34 | ||
| Q2 25 | $-3.77 | $0.29 | ||
| Q1 25 | $-0.19 | $0.22 | ||
| Q4 24 | $-2.54 | $0.22 | ||
| Q3 24 | $-0.30 | $0.28 | ||
| Q2 24 | $-2.20 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $116.5M |
| 总债务越低越好 | $2.5B | $650.6M |
| 股东权益账面价值 | $2.0B | $1.4B |
| 总资产 | $5.7B | $3.2B |
| 负债/权益比越低杠杆越低 | 1.23× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资QDELROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | — | $100.0M | ||
| Q3 25 | $98.1M | $127.4M | ||
| Q2 25 | $151.7M | $123.0M | ||
| Q1 25 | $127.1M | $201.2M | ||
| Q4 24 | $98.3M | $89.6M | ||
| Q3 24 | $143.7M | $95.3M | ||
| Q2 24 | $107.0M | $106.7M |
总债务QDELROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | $2.5B | $485.7M | ||
| Q2 25 | $2.1B | $485.3M | ||
| Q1 25 | $2.1B | $485.5M | ||
| Q4 24 | $2.1B | $395.3M | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
股东权益QDELROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | $2.0B | $1.5B | ||
| Q2 25 | $2.8B | $1.4B | ||
| Q1 25 | $3.0B | $1.4B | ||
| Q4 24 | $3.0B | $1.3B | ||
| Q3 24 | $3.2B | $1.3B | ||
| Q2 24 | $3.2B | $1.2B |
总资产QDELROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | — | $3.1B | ||
| Q3 25 | $5.7B | $3.2B | ||
| Q2 25 | $6.4B | $3.2B | ||
| Q1 25 | $6.5B | $2.9B | ||
| Q4 24 | $6.4B | $2.8B | ||
| Q3 24 | $6.8B | $2.8B | ||
| Q2 24 | $6.7B | $2.8B |
负债/权益比QDELROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | 1.23× | 0.32× | ||
| Q2 25 | 0.74× | 0.34× | ||
| Q1 25 | 0.70× | 0.36× | ||
| Q4 24 | 0.72× | 0.30× | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $111.2M |
| 自由现金流率自由现金流/营收 | -13.5% | 12.3% |
| 资本支出强度资本支出/营收 | 7.0% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $621.1M |
8季度趋势，按日历期对齐
经营现金流QDELROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | — | $164.7M | ||
| Q3 25 | $-45.5M | $191.3M | ||
| Q2 25 | $-46.8M | $175.1M | ||
| Q1 25 | $65.6M | $146.9M | ||
| Q4 24 | $63.7M | $188.2M | ||
| Q3 24 | $117.9M | $146.9M | ||
| Q2 24 | $-97.9M | $145.1M |
自由现金流QDELROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | — | $159.0M | ||
| Q3 25 | $-94.7M | $182.8M | ||
| Q2 25 | $-84.3M | $168.0M | ||
| Q1 25 | $9.4M | $140.1M | ||
| Q4 24 | $16.5M | $184.0M | ||
| Q3 24 | $71.4M | $139.4M | ||
| Q2 24 | $-133.2M | $136.4M |
自由现金流率QDELROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | — | 17.4% | ||
| Q3 25 | -13.5% | 17.8% | ||
| Q2 25 | -13.7% | 16.8% | ||
| Q1 25 | 1.4% | 17.0% | ||
| Q4 24 | 2.3% | 22.1% | ||
| Q3 24 | 9.8% | 15.2% | ||
| Q2 24 | -20.9% | 15.3% |
资本支出强度QDELROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | 7.0% | 0.8% | ||
| Q2 25 | 6.1% | 0.7% | ||
| Q1 25 | 8.1% | 0.8% | ||
| Q4 24 | 6.7% | 0.5% | ||
| Q3 24 | 6.4% | 0.8% | ||
| Q2 24 | 5.5% | 1.0% |
现金转化率QDELROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
ROL
暂无分部数据
